469 related articles for article (PubMed ID: 28916757)
1. Muscle pathology from stochastic low level DUX4 expression in an FSHD mouse model.
Bosnakovski D; Chan SSK; Recht OO; Hartweck LM; Gustafson CJ; Athman LL; Lowe DA; Kyba M
Nat Commun; 2017 Sep; 8(1):550. PubMed ID: 28916757
[TBL] [Abstract][Full Text] [Related]
2. Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity.
Jones TI; Chew GL; Barraza-Flores P; Schreier S; Ramirez M; Wuebbles RD; Burkin DJ; Bradley RK; Jones PL
Skelet Muscle; 2020 Apr; 10(1):8. PubMed ID: 32278354
[TBL] [Abstract][Full Text] [Related]
3. p53-independent DUX4 pathology in cell and animal models of facioscapulohumeral muscular dystrophy.
Bosnakovski D; Gearhart MD; Toso EA; Recht OO; Cucak A; Jain AK; Barton MC; Kyba M
Dis Model Mech; 2017 Oct; 10(10):1211-1216. PubMed ID: 28754837
[TBL] [Abstract][Full Text] [Related]
4. Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis.
Jones TI; Chen JC; Rahimov F; Homma S; Arashiro P; Beermann ML; King OD; Miller JB; Kunkel LM; Emerson CP; Wagner KR; Jones PL
Hum Mol Genet; 2012 Oct; 21(20):4419-30. PubMed ID: 22798623
[TBL] [Abstract][Full Text] [Related]
5. Expression of DUX4 in zebrafish development recapitulates facioscapulohumeral muscular dystrophy.
Mitsuhashi H; Mitsuhashi S; Lynn-Jones T; Kawahara G; Kunkel LM
Hum Mol Genet; 2013 Feb; 22(3):568-77. PubMed ID: 23108159
[TBL] [Abstract][Full Text] [Related]
6. Influence of
Duranti E; Villa C
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298453
[TBL] [Abstract][Full Text] [Related]
7. Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics.
Chen JC; King OD; Zhang Y; Clayton NP; Spencer C; Wentworth BM; Emerson CP; Wagner KR
Mol Ther; 2016 Aug; 24(8):1405-11. PubMed ID: 27378237
[TBL] [Abstract][Full Text] [Related]
8. DUX4 expression in FSHD muscle cells: how could such a rare protein cause a myopathy?
Tassin A; Laoudj-Chenivesse D; Vanderplanck C; Barro M; Charron S; Ansseau E; Chen YW; Mercier J; Coppée F; Belayew A
J Cell Mol Med; 2013 Jan; 17(1):76-89. PubMed ID: 23206257
[TBL] [Abstract][Full Text] [Related]
9. DUX4 Signalling in the Pathogenesis of Facioscapulohumeral Muscular Dystrophy.
Lim KRQ; Nguyen Q; Yokota T
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31979100
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional and cytopathological hallmarks of FSHD in chronic DUX4-expressing mice.
Bosnakovski D; Shams AS; Yuan C; da Silva MT; Ener ET; Baumann CW; Lindsay AJ; Verma M; Asakura A; Lowe DA; Kyba M
J Clin Invest; 2020 May; 130(5):2465-2477. PubMed ID: 32250341
[TBL] [Abstract][Full Text] [Related]
11. The Genetics and Epigenetics of Facioscapulohumeral Muscular Dystrophy.
Himeda CL; Jones PL
Annu Rev Genomics Hum Genet; 2019 Aug; 20():265-291. PubMed ID: 31018108
[TBL] [Abstract][Full Text] [Related]
12. Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model.
Lu-Nguyen N; Malerba A; Herath S; Dickson G; Popplewell L
Hum Mol Genet; 2021 Jul; 30(15):1398-1412. PubMed ID: 33987655
[TBL] [Abstract][Full Text] [Related]
13. Muscle eosinophilia is a hallmark of chronic disease in facioscapulohumeral muscular dystrophy.
Nunes AM; Ramirez MM; Garcia-Collazo E; Jones TI; Jones PL
Hum Mol Genet; 2024 May; 33(10):872-883. PubMed ID: 38340007
[TBL] [Abstract][Full Text] [Related]
14. PAX7 target gene repression is a superior FSHD biomarker than DUX4 target gene activation, associating with pathological severity and identifying FSHD at the single-cell level.
Banerji CRS; Zammit PS
Hum Mol Genet; 2019 Jul; 28(13):2224-2236. PubMed ID: 31067297
[TBL] [Abstract][Full Text] [Related]
15. A complex interplay of genetic and epigenetic events leads to abnormal expression of the DUX4 gene in facioscapulohumeral muscular dystrophy.
Gatica LV; Rosa AL
Neuromuscul Disord; 2016 Dec; 26(12):844-852. PubMed ID: 27816329
[TBL] [Abstract][Full Text] [Related]
16. Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy.
Oliva J; Galasinski S; Richey A; Campbell AE; Meyers MJ; Modi N; Zhong JW; Tawil R; Tapscott SJ; Sverdrup FM
J Pharmacol Exp Ther; 2019 Aug; 370(2):219-230. PubMed ID: 31189728
[TBL] [Abstract][Full Text] [Related]
17. Identification of candidate miRNA biomarkers for facioscapulohumeral muscular dystrophy using DUX4-based mouse models.
Nunes AM; Ramirez M; Jones TI; Jones PL
Dis Model Mech; 2021 Aug; 14(8):. PubMed ID: 34338285
[TBL] [Abstract][Full Text] [Related]
18. A feedback loop between nonsense-mediated decay and the retrogene DUX4 in facioscapulohumeral muscular dystrophy.
Feng Q; Snider L; Jagannathan S; Tawil R; van der Maarel SM; Tapscott SJ; Bradley RK
Elife; 2015 Jan; 4():. PubMed ID: 25564732
[TBL] [Abstract][Full Text] [Related]
19. Persistent Fibroadipogenic Progenitor Expansion Following Transient DUX4 Expression Provokes a Profibrotic State in a Mouse Model for FSHD.
Bosnakovski D; Oyler D; Mitanoska A; Douglas M; Ener ET; Shams AS; Kyba M
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216102
[TBL] [Abstract][Full Text] [Related]
20. It's not all about muscle: fibroadipogenic progenitors contribute to facioscapulohumeral muscular dystrophy.
Serra C; Wagner KR
J Clin Invest; 2020 May; 130(5):2186-2188. PubMed ID: 32250345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]